Five updates:
1. Bioventus launched its initial public offering: 7.35 million shares of its Class A common stock priced between $16 and $18 per share.
2. Larry Chen was appointed as managing director of the company’s China and Asian Pacific region.
3. Bioventus has acquired rehabilitation solutions company Bioness for $45 million upfront consideration, with up to $65 million contingent consideration.
4. In the first quarter of 2021, Bioventus saw year-over-year net income growth, roping in $24.5 million.
5. Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable. The allograft is optimal for minimally invasive surgeries and can be used in a various spine and foot and ankle procedures.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
